Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.32|
|52 Week High||US$4.00|
|52 Week Low||US$15.65|
|1 Month Change||-8.86%|
|3 Month Change||-7.89%|
|1 Year Change||-41.78%|
|3 Year Change||-40.08%|
|5 Year Change||-68.90%|
|Change since IPO||-76.20%|
Recent News & Updates
Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Will Probably Find It Hard To See A Huge Raise This Year
In the past three years, the share price of Syros Pharmaceuticals, Inc. ( NASDAQ:SYRS ) has struggled to grow and now...
Syros Pharma up 18% day after ARK Innovation dumps shares
Syros Pharmaceuticals (SYRS) shares are up more than 18% in afternoon trading, a day after Cathie Wood's ARK Innovation ETF (ARKK) liquidated its position in the company.Wood unloaded ~3.6M Syros shares yesterday, which represented 0.09% of the fund's holdings.One possible explanation for the rise in shares is that the company yesterday held a key opinion leader webcast discussing SY-1425 in newly diagnosed higher-risk myelodysplastic syndrome.The candidate is an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist.ARK Innovation shares are up 0.2% to $111.64
|SYRS||US Biotechs||US Market|
Return vs Industry: SYRS underperformed the US Biotechs industry which returned 17.8% over the past year.
Return vs Market: SYRS underperformed the US Market which returned 31.5% over the past year.
Stable Share Price: SYRS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: SYRS's weekly volatility (9%) has been stable over the past year.
About the Company
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company’s lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd.
Syros Pharmaceuticals Fundamentals Summary
|SYRS fundamental statistics|
Is SYRS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SYRS income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.39|
|Net Profit Margin||-442.38%|
How did SYRS perform over the long term?See historical performance and comparison
Is Syros Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SYRS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SYRS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SYRS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: SYRS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SYRS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SYRS is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (2.9x).
How is Syros Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SYRS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SYRS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SYRS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SYRS's revenue (64.8% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: SYRS's revenue (64.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SYRS's Return on Equity is forecast to be high in 3 years time
How has Syros Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SYRS is currently unprofitable.
Growing Profit Margin: SYRS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SYRS is unprofitable, and losses have increased over the past 5 years at a rate of 12.2% per year.
Accelerating Growth: Unable to compare SYRS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SYRS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: SYRS has a negative Return on Equity (-66.42%), as it is currently unprofitable.
How is Syros Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: SYRS's short term assets ($186.2M) exceed its short term liabilities ($27.6M).
Long Term Liabilities: SYRS's short term assets ($186.2M) exceed its long term liabilities ($76.1M).
Debt to Equity History and Analysis
Debt Level: SYRS's debt to equity ratio (30.7%) is considered satisfactory.
Reducing Debt: SYRS's debt to equity ratio has increased from 0% to 30.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SYRS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SYRS has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 16.4% each year.
What is Syros Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SYRS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SYRS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SYRS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SYRS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SYRS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nancy Simonian (60 yo)
Dr. Nancy A. Simonian, M.D., has been the Chief Executive Officer at Syros Pharmaceuticals, Inc. since July 2012 and serves as its President. Dr. Simonian had been Interim Principal Financial Officer and P...
CEO Compensation Analysis
Compensation vs Market: Nancy's total compensation ($USD2.53M) is above average for companies of similar size in the US market ($USD1.08M).
Compensation vs Earnings: Nancy's compensation has been consistent with company performance over the past year.
Experienced Management: SYRS's management team is seasoned and experienced (5.8 years average tenure).
Experienced Board: SYRS's board of directors are considered experienced (8.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.3%.
Syros Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Syros Pharmaceuticals, Inc.
- Ticker: SYRS
- Exchange: NasdaqGS
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$267.541m
- Shares outstanding: 61.93m
- Website: https://www.syros.com
Number of Employees
- Syros Pharmaceuticals, Inc.
- 35 CambridgePark Drive
- 4th Floor
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 23:05|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.